Patent application number | Description | Published |
20110150850 | REDUCED COLONIZATION OF MICROBES AT THE MUCOSA - The invention is in the field of use of engineered microbes for the delivery and administration of therapeutic peptides or proteins to humans or animals suffering from a disease, or the use of engineered microbes for the delivery of antigens such as for vaccination purposes. More in particular, the invention relates to a recombinant microbe that has reduced capacity of colonizing the mucosa in comparison to its wild type ancestor, in particular when residing in the alimentary tract as part of a treatment or vaccination of a human or animal. In particular, the recombinant microbe contains an inactive thymidylate synthase gene that causes the reduced capability for the microbe to colonize in the alimentary tract. The invention also covers the use of said recombinant microbes comprising nucleic acids or vectors for expressing heterologous or homologous proteins; and also for delivery, especially therapeutic delivery, of the said proteins to animals or humans. | 06-23-2011 |
20120183503 | LACTOBACILLUS AND STREPTOCOCCUS PROMOTERS AND USES THEREOF - The invention is in the field of molecular biology, and relates to recombinant engineering and protein expression. More in particular, the invention relates to nucleic acids for recombinant expression of proteins comprising sequences derived from | 07-19-2012 |
20130164380 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS - The present invention provides methods and compositions for treating inflammatory bowel disease, including ulcerative colitis and Crohn's Disease, and other related conditions, by locally administering to the intestinal mucosa of a subject having inflammatory bowel disease a therapeutically effective amount of IL-27 or a therapeutic variant or fragment thereof. The invention further provides a method to treat inflammatory bowel disease comprising administering to the subject a recombinant microorganism capable of producing a therapeutically effective amount of IL-27 or a variant or fragment thereof in situ in the intestinal mucosa. | 06-27-2013 |
20140105863 | POLYCISTRONIC EXPRESSION SYSTEM FOR BACTERIA - The invention relates to polycistronic expression in gram-positive bacterium and in particular concerns polycistronic expression units comprising one or more gene endogenous to the gram-positive bacterium transcriptionally coupled to one or more genes exogenous to the bacterium. | 04-17-2014 |
20140234371 | MODIFIED GRAM POSITIVE BACTERIA AND USES THEREOF - The present invention relates to a gram positive bacterium, preferably a lactic acid bacterium (LAB) or | 08-21-2014 |